A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 203 KB, text/html
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) Omicron variant sub-lineages spread rapidly worldwide, mostly due to their immune-evasive properties. This has put a significant part of the population at risk for severe disease and underscores the need for effective anti-SARS-CoV-2 agents against emergent strains in vulnerable patients. Camelid nanobodies are attractive therapeutic candidates due to their high stability, ease of large-scale production, and potential for delivery via inhalation. Here, we characterize the receptor binding domain (RBD)-specific nanobody W25 and show superior neutralization activity toward Omicron sub-lineages in comparison to all other SARS-CoV2 variants. Structure analysis of W25 in complex with the SARS-CoV2 spike glycoprotein shows that W25 engages an RBD epitope not covered by any of the antibodies previously approved for emergency use. In vivo evaluation of W25 prophylactic and therapeutic treatments across multiple SARS-CoV-2 variant infection models, together with W25 biodistribution analysis in mice, demonstrates favorable pre-clinical properties. Together, these data endorse W25 for further clinical development.
Original language | English |
---|---|
Article number | 107085 |
Journal | iScience |
Volume | 26 |
Issue number | 7 |
Number of pages | 26 |
ISSN | 2589-0042 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:
© 2023
- Decision science, Information system model, Public health
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 358966320